Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
May 13, 2024 08:00 ET | Compass Therapeutics
Received FDA Fast Track Designation for the investigation of CTX-009 in combination with paclitaxel for the treatment of patients with metastatic or locally advanced biliary tract tumors. Enrollment...
Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial
February 28, 2024 08:00 ET | Compass Therapeutics
CTX-8371, a bispecific checkpoint inhibitor that simultaneously targets PD-1 and PD-L1, exhibits a novel mechanism-of-action leading to proteolytic cleavage and subsequent loss of cell surface...
Compass Therapeutics Presents Data on CTX-8371, a Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting
April 08, 2022 13:01 ET | Compass Therapeutics
BOSTON, April 08, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage oncology focused biotechnology company developing proprietary antibody-based therapeutics to...
Cancer Advances logo.jpg
Cancer Advances, Inc. Announces Publication, "Gastrin Vaccine Alone and in Combination with an Immune Checkpoint Antibody Inhibits Growth and Metastases of Gastric Cancer" in Frontiers in Oncology
December 06, 2021 10:00 ET | Cancer Advances Inc
DURHAM, N.C., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, announces a new publication in...
Catalym logo.jpg.png
CatalYm to Present Initial Data of First-in-Human Trial of GDF-15 neutralizing antibody CTL-002 at the 2021 ASCO Annual Meeting
May 20, 2021 03:30 ET | CatalYm GmbH
MUNICH, Germany, May 20, 2021 (GLOBE NEWSWIRE) -- CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced that their abstract with first interim data from...
Sorrento Receives FDA Clearance to Proceed With Phase 2 Study for Sti-3031, an Anti-Pd-L1 Antibody, for Advanced Urothelial Carcinoma
April 27, 2021 11:39 ET | Sorrento Therapeutics, Inc.
STI-3031 was discovered from Sorrento’s fully human G-MAB™ library.Currently, six G-MAB antibodies are in Phase 1b through Phase 3 clinical trials in immuno-oncology and COVID-19 indications.These...
Lee’s Pharmaceutical Announces its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Clearance to Start Phase 3 Trial as a First-line Treatment of Extensive-stage Small-Cell Lung Cancer
March 07, 2021 22:27 ET | Sorrento Therapeutics, Inc.
Socazolimab is an anti-PD-L1 antibody licensed from Sorrento for the Greater China Territory by Lee’s Pharm.China’s National Medical Products Administration (“NMPA”) clears Lee’s Pharm to conduct a...
Lee’s Pharmaceutical Announces Its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Breakthrough Therapy Designation in China for the Treatment of Recurrent or Metastatic Cervical Cancer
February 09, 2021 09:00 ET | Sorrento Therapeutics, Inc.
Socazolimab is an anti-PD-L1 antibody licensed from Sorrento for the Greater China Territory by Lee’s Pharma.China National Medical Products Administration (NMPA) grants breakthrough Therapy...
Inspirata and Flagsh
Inspirata and Flagship Biosciences Announce New Technical Partnership and Integration at Pathology Visions 2020
October 27, 2020 11:00 ET | Inspirata, Inc.
Tampa, Florida / Westminster, Colorado, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Cancer informatics and digital pathology provider Inspirata announced today a new technical partnership with clinical...
CORRECTING and REPLACING - Yuhan Corp and Sorrento Therapeutics Announce Completion of Phase 1 Clinical Study of Anti-PD-L1 Antibody IMC-001
March 11, 2019 12:54 ET | Sorrento Therapeutics, Inc.
SEOUL, South Korea and SAN DIEGO, March 11, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Sorrento Therapeutics, Inc. (Nasdaq: SRNE), please note that in the...